TRACER RGD-K5 Carotid Plaque Imaging Study

• Status: Terminated
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the ability of the compound[F-18]RGD-K5, when used as a tracer during PET (positron emission tomography) imaging, to detect regions of unstable atherosclerotic plaque in the carotid artery of subjects being considered for carotid endarterectomy (CEA),and to confirm this ability through histological studies of samples of carotid artery plaques that will be collected during the planned carotid surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Balaji Tamarappoo; The Cleveland Clinic

Criteria

Inclusion Criteria:

• Participant is a female or male of any race/ethnicity >18 years old at the time of the investigational product administration

• Participant or participant's legally acceptable representative provides written informed consent

• Participant is capable of complying with study procedures

• Participant has known carotid artery stenosis of >50% luminal diameter based on carotid ultrasound or computed tomography angiography (CTA), as stated in official clinical report or as measured by PI if no quantitative assessment appears in the report, and who is deemed to be a surgical candidate for endarterectomy

• Participant has had a carotid ultrasound and/or computed tomography angiography (CTA) and the report is available for collection

• Participant has had or is scheduled to have a carotid CT angiogram for plaque localization within 60 days of signing ICF (or else scheduled CTA must be performed on a separate day and prior to the investigational PET procedure)

• Participant has consented to have an endarterectomy

• Participant will be scheduled for an investigational[F-18]RGD-K5 PET/CT scan within 4 weeks prior to endarterectomy

• Participant must have renal functions values as defined by laboratory results within the following ranges:

• Serum creatinine ≤ 1.5 mg/dL

• Estimated glomerular filtration rate (eGFR): ≥ 45mL/min

Exclusion Criteria:

• Female participant is nursing

• Female participant is pregnant

• Participant has been involved in an investigative, radioactive research procedure within the past 14 days

• Participant has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality

• Participant has a history or current evidence of any condition, therapy, lab abnormality that, in the opinion of the study investigator or treating physicians might confound the results of the study or poses an additional risk to the participants by their participation in the study